Table 3.
Comparison of liver biochemistry/function before and after treatment
| Item | Case group (n =36) | Control group (n =36) | |||||
|---|---|---|---|---|---|---|---|
| Before treatment | 1 week after treatment | 8 weeks after treatment | Before treatment | 1 week after treatment | 8 weeks after treatment | ||
| ALT | 35.00±2.27 | 42.84±2.55a | 36.22±2.93 | 33.42±2.61 | 43.02±3.74a | 34.55±2.86 | |
| AST | 41.88±2.54 | 47.11±2.98a | 43.16±2.96 | 40.96±2.79 | 48.14±3.51a | 42.29±2.96 | |
| DBIL | 5.63±1.62 | 7.47±1.64a | 6.25±0.99 | 5.39±1.35 | 7.04±1.03a | 5.93±0.92 | |
| AFP | 124.35±100.00 | NA | 49.78±28.89a | 140.82±109.05 | NA | 64.83±42.78a | |
| PAB | 316.4±21.93 | 307.50±16.52 | 309.2±20.41 | 315.9±20.72 | 233.6±31.25a | 307.10±17.71 | |
| ALB | 32.10±1.87 | 32.94±1.73 | 39.87±2.28a | 32.26±1.68 | 31.89±1.70 | 32.92±1.51 | |
| INR | 1.09±0.11 | 1.14±0.09 | 1.07±0.13 | 1.13±0.11 | 1.17±0.09 | 1.16±0.08 | |
Notes: case group were treated with FJXF combined TACE; control group were treated with TACE alone. ALT: alanine aminotransferase; AST: aspartate transferase; DBIL: direct bilirubin; AFP: alpha-fetoprotein; PAB: prealbumin; ALB: albumin; INR: international standardized ratio of coagulation; NA: not applicable; aP < 0.05 compared with before treatment in each group.